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Behçet's disease (BD), a systemic vasculitis disorder is associated with the Silk Road. Oral aphtous and genital 
ulcers, cutaneous pseudo folliculitis and uveitis are the most common manifestations. These manifestations are 
frequently associated with neurological symptoms, pulmonary involvement and arthritis. The etiology remains 
uncertain and the most fashionable hypothesis is immunological. BD disease is thought to be caused by 
pathogenic helper T (Th) cells. Th1, Th2, Th17 and Treg cells have been implicated in its pathogenesis. Recently 
spotlight has been drawn to novel cytokine of the IL-1 family: interleukin-37 (IL-37). Since its discovery, IL-37 
has been studied extensively in immunological field. It has been established that IL-37 inhibits innate and 
adaptive immunity through suuppression of pro-inflammatory molecules. This review will discuss the role of 
IL-37 in BD. 
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monocyte-chemoattractant protein-5; rIL-37, Recombinant IL-37；ROS, reactive oxygen species. 
Introduction 
Behçet’s disease (BD) is a chronic relapsing/remitting 
multi-system disease of poorly understood aetiology, 
primarily characterised by oro-genital ulceration but also 
affecting other body systems including the eye, joints and 
skin [1, 2]. BD can be life-threatening in severe forms where 
the disease progresses to involve the large blood vessels, 
central nervous and pulmonary systems or the 
gastrointestinal tract. The disease is increased approximately 
six-fold in patients with HLA-B51/B5 genetic 
polymorphisms [3] and is widely regarded as an 
auto-inflammatory condition although autoimmune responses 
to certain specific antigen have been described in the disease 
[4]. Infection by herpes viruses family (EBV, HSV1) were 
also thought to be important in both the initiation and in 
triggering acute exacerbations of affected systems in BD [5, 6]. 
BD is considered a T-cell-mediated disease [7-9]. Although 
much has been learned during recent years on the 
pathogenesis, it is still an important cause of morbidity and 
mortality in the areas where it is prevalent. As BD lacks 
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specific symptoms and laboratory findings, the diagnosis 
relies on clinical criteria.  
Immunological modifications modulate disease onset, 
progression and outcome of BD. Peripheral blood 
mononuclear cells (PBMCs) and inflammatory sites (skin 
lesions, cerebrospinal fluid, bronchoalveolar lavage) from 
patients with BD expressed dysregulated Th1/Th2, 
Th17/Treg ratios [10-11]. Multiple studies demonstrated that 
inflammatory mediators are highly expressed in patients with 
BD compared to healthy controls [12], mainly represented by 
Th1 and Th17 cells cytokines. In the same way, genetic 
polymorphisms of inflammatory mediators are associated 
with disease susceptibility and evolution [13].  
The association of the IL-1 cluster gene polymorphisms 
with the development of BD was investigated [14] and 
lightened the field through characterization of new 
immunological parameters including pro-inflammatory 
agonists (IL-33) [15-18] and putative antagonists (IL-37) [19-20] 
mediators.  
Functional analysis using neutralizing monoclonal 
antibodies treated human PBMCs indicated that the IL-1 
family of cytokines might play an importantly role in the 
development of autoimmune/inflammatory diseases [21]. 
IL-37 is a newly discovered cytokines able to modulate 
innate immune cells that has been studied in several diseases 
regarding its anti-inflammatory capacity. The association of 
cytokines with BD on multiple levels promotes us to 
systematically review what had been published recently on 
the crucial nature of IL-37 in relation to the inflammation 
pathways gaining attention for its regulatory capability in this 
multisystemic disorder. The information obtained may lead 
to a better understanding of the insights into IL-37 in BD. 
Biological functions of IL-37 
Human PBMCs treated with the neutralizing monoclonal 
anti-IL-37 was able to increase inflammatory cytokines 
production, such as IL-1β, IL-6 and tumor necrosis factor 
(TNF)-α [22]. Similarly, PBMCs transfected with siRNA to 
IL-37 reduce the IL-37 protein abundance, leading to 
increases in the generation of IL-β, IL-6, and TNF-α when 
stimulated with LPS or Pam3CSK4 [22].  
In IL-37 transgenic (IL-37tg) mice, bone marrow-induced 
DCs (BMDCs) stimulated with LPS exhibited a decreased 
expression of MHCII and CD40 expression compared with 
wild-type (WT) mice controls [23]. When syngeneic T cells, 
or allogeneic T cells were co-cultured with dendritic cells 
from wild type mice, proliferation of CD4+ and CD8+ T cells 
increased significantly. When splenic T cells cocultured with 
BMDCs from WT mice, there was induced expression of 
CD4+ CD25+ Foxp3+ Treg cells. Notably, BMDCs from 
IL-37tg mice, promoted Treg cells expansion [23]. Mouse 
macrophage RAW cell line can stably express the human 
IL-37b isoform. IL-37b transfection effectively reduce 
LPS-stimulated TNF-α, macrophage inflammatory protein-2 
(MIP-2), IL-1α and IL-6 expression in comparison with 
mock transfected RAW cells, and production of macrophage 
colony-stimulating factor (M-CSF), B-cell-attracting 
chemokine-1 (BCA-1), granulocyte macrophage 
colony-stimulating factor (GM-CSF), IL-1β, 
monocyte-chemoattractant protein-5 (MCP-5), IL-23 was 
considerably reduced in IL-37 treated RAW cells [22]. The 
epithelial cell line A549 transfected with IL-37b 
down-regulated constitutive and IL-1β-induced IL-6 and 
IL-1α expression [23]. A549 cells or THP-1 cells transfected 
with IL-37b displayed colocalization of IL-37 and Smad3. 
IL-37b expressing RAW cells treated with Smad3 specific 
inhibitor SIS3 can reverse the inhibition of IL-6 and IL-1α 
expression, and THP-1 cells treated with SIS3 can 
up-regulate IL-1β expression. THP-1 cells depleted of Smad3 
by lentiviral shRNA and then challenged with IL-37, 
showing with reduced expression of IL-1β or LPS induced 
IL-8, IL-6 [23]. Collectively, these data suggest that IL-37 
plays an anti-inflammatory effect in human PBMCs, mice 
BMDCs, and regulates the production of inflammatory 
components in cell lines partly mediated by Smad3. 
Recombinant IL-37 (rIL-37) suppressed joint 
inflammation, reduced cell influx and lowered histological 
scores in experimental arthritis [24]. Low doses of IL-37 (40 
µg/kg) suppressed joint inflammation by 51.7% and 
significantly decreased synovial IL-1β by 84%, IL-6 by 73%, 
TNF-α by 33%, chemokine (C-X-C motif) ligand 1 by 58%, 
Chemokine (C-C motif) ligand 3 or macrophage 
inflammatory protein 1- alpha by 64%, IL-1a by 40% and 
MPO by 60%. The activity of IL-37 was associated with a 
lower recruitment of neutrophils into the joint [24].  
IL-37 was also proposed as new therapeutic strategies that 
can be used as immunosuppressive anti-inflammatory 
cytokine in psoriasis and other inflammatory cutaneous 
diseases [25] reducing CXCL8, IL-6, and S100A7 levels. 
IL-37 and its receptor 
Human IL-37 is a member of the IL-1 gene family (Fig. 
1). There are 11 members in the IL-1 family, seven of which 
are pro-inflammatory agonists and four of which are receptor 
antagonists. The agonists are involved in the innate immune 
system and are generated after Toll-like receptor stimulation 
[26-27]. Whether IL-37 is an antagonist or an agonist of the 
immune system is still not well defined, but studies have 
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shown that it suppresses innate immune responses [28]. Based 
on their precursor’s length and each precursor’s propiece 
length, members of the IL-1 family are further divided into 
subfamilies: IL-1 subfamily, IL-18 subfamily, and IL-36 
subfamily. IL-37 belongs to IL-18 subfamily (Figure 1). IL-1 
subfamily has the longest propieces, and IL-18 subfamily has 
shorter ones. The mechanism of removal of its propiece is 
still not well known [29]. In humans, IL-37 gene can be found 
on chromosome 2 along with the genes from 8 other 
members of the IL-1 family. It is made up of 12 β-barrel 
strands, with an IL-1 family structural pattern that is closer to 
that of IL-18 [30]. There are five splice transcript variants for 
this interleukin that encode distinct isoforms (IL-37a-IL-37e) 
[30]. The largest of the isotypes is IL-37b, and it has 5 of the 6 
exons. IL-37b is the isoform that is biologically functional 
and can produce homodimers; other isoforms are either not 
functional, or their function is undetermined [31 - 32]. 
Figure 1. Model for IL-1 family signaling. IL-1 family is divided into three subfamilies based on the length of the N-terminal propieces, (1) 
IL-1 subfamily: IL-1𝛼, IL-𝛽, IL-1 receptor antagonist (IL-1Ra), and IL-33. (2) IL-18 subfamily: IL-18 and IL-37. (3) IL-36 subfamily: IL-36𝛼, 
IL-36𝛽, IL-36𝛾, and IL-38. The receptor for each IL-1 family cytokine is a heterodimer of the proper or common subunits. IL-1R1, ST2, 
IL-18R𝛼, and IL-36R are ligand-binding subunits, while IL-1R accessory protein (IL-1LRAcP), IL-18R𝛽, SIGIRR (single immunoglobulin 
IL-1-related receptor) are signaling subunits. When IL-1 family cytokines bind to the corresponding ligands, they recruit the corresponding 
signaling receptor subunit, and therefore translocates nuclear factor- (NF-) 𝜅B to the nucleus and activates MAPKs (p38, JNK, ERK) 
pathways.  
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Monocytes, macrophages, synovial cells, plasma cells as 
well as epithelial cells of the skin, and intestine expressed 
IL-37 protein. The abundance of IL-37 transcripts is low in 
PBMCs and DCs is due to an instability sequence in IL37. 
This instability sequence limits mRNA half-life of IL-37 [33]. 
Indeed, despite having a CMV promoter, resting mRNA 
levels for IL-37 in IL37-tg mice is either absent or low but 
rapidly increases with inflammation [23]. Despite low 
production, recombinant IL-37 is highly active, low 
concentrations of recombinant IL-37 were able to reduce 
LPS-induced IL-1β, IL-6, and TNF-α production in vitro [21;
33].  
IL-37 in Behçet’s Disease 
There is no extensive investigation on IL-37 and its role in 
regard to its biological role in BD [19-20]. These features will 
be discussed in this short review. 
There were lower levels of IL-37 in BD patients compared 
to healthy subjects [19-20]. IL-37 mRNAs expression and 
serum levels were decreased in BD patients compared to 
healthy controls. This inhibition was more pronounced in 
active BD patients suggesting its correlation with BD disease 
activity, a low level of IL-37 likely contributing to disease 
severity [19-20]. The decreased IL-37 level in BD was 
associated with increased production of IL-1β, IL-6, and 
TNF-α in LPS-stimulated PBMCs [19, 20]. In vitro 
experiments showed that addition of recombinant IL-37 
(rIL-37) significantly suppressed the production of these 3 
pro-inflammatory cytokines.  
IL-37 exerted a more suppressive effect on IL-17 
production in active BD patients than in healthy controls [19]. 
rIL-37-treated dendritic cells (DCs) in BD remarkably 
inhibited Th17 and Th1 cell responses as compared to 
control DCs [19, 20]. Pay et al. reported abnormalities in DCs 
from BD patients [34]. 
Treatment with steroids might be able to return the 
expression of IL-37 back to subnormal levels, particularly 
when drug was used at high doses. The restored IL-37 level 
in inactive BD was associated with regression of symptoms 
corresponding to clinical remission and inactive BD phase. 
Recent data from Ye et al. showed that rIL-37 significantly 
inhibited reactive oxygen species (ROS) production and 
promoted IL-27 production in association with a 
down-regulated activation of mitogen-activated protein 
Figure 2. Schematic representation of the potential interactions between IL-33 and IL-37 in Th1 immunity in Behçet’s disease. 
IL-33 drivers type 1 inflammatory conditions including Behçet’s disease through promoting Th1 cells proliferation and related cytokines 
generation, as well as Th1 polarization via dendritic cell. By contrast IL-37 play immunoregulatory roles in Th1 immunity inducing IL-10 
production and promoting regulatory T cells (Treg) proliferation and suppressing IL-17 synthesis and inhibiting IL-1𝛼, TNF-𝛼, IL-6.  
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kinase (MAPK) in DCs [19]. In fact, rIL-37-treated DCs had a 
significant inhibitory effect on the Th1 and Th17 cytokine 
response. The decrease in IL-37 gene expression observed in 
patients with active BD could be responsible of DCs 
malfunctioning [19]. 
The perspectives of the potential therapeutic modality 
using IL-37 in inflammatory diseases 
IL-37 expression was found increased in systemic lupus 
erythematosus (SLE) [35-37] and in RA synovial cells [38-41]. 
The reasons to this contrast in IL-37 expression between BD 
and other inflammatory conditions are not clear, but may be 
due to differences in the immunological mechanism 
reactions, inducing a particular and different “anticipative” 
immune system against inflammation.  
Recent findings have revealed the therapeutic potential of 
IL-37 in inflammatory diseases. Active RA patients exhibited 
higher IL-37 levels compared with patients in remission and 
controls [42]. On the contrary, IL-17 and IL-17-driving 
cytokine production were markedly reduced in synovium and 
joint cells from CIA mice receiving injection of IL-37. 
ApoE-deficient diabetic mice injected with IL-37 showed 
significantly less calcification areas detected by both von 
Kossa and Alizarin Red staining, and much smaller plaque 
size of the atherosclerotic lesions and lower plaque 
vulnerability scores detected by hematoxylin-eosin staining 
in the aorta root [43]. Collectively, these data suggest the 
potential therapeutic modality using IL-37 in inflammatory 
diseases. Human IL-37 VAr2 exerts less inhibition on 
proinflammatory cytokine production than did other IL-37 
variant. Conversely, purified extracellular IL-37 variant 
proteins demonstrated comparable inhibitory abilities in 
vitro. This study reveals that common genetic variants of 
IL37 lead to different immune-inhibitory potencies, primarily 
as a result of differences in IL-37 protein stability, suggesting 
the possible involvement of these variants in various human 
diseases. 
Conclusions 
Evaluating the important roles of IL-37 in regulating T 
cells, DCs began to shed an interesting light on the 
understanding of immune-pathologic mechanism in BD. 
Dysregulated IL-37 is observed in BD patients. In addition, 
functional analysis has showed that supplementing IL-37 in 
BD patients demonstrated development and push down 
inflammation. Since decreased protein and mRNA IL-37 
levels correlate with BD susceptibility. An adequate 
manipulation of IL-37 pathway might be critical for 
regulating normal immune responses. With the advent of 
more advanced technology and emergence of more elegant 
studies in the future, the enhanced understanding of the 
molecular and cellular targets of IL-37 will be indeed helpful 
to interpret the pathogenesis of BD (Fig. 2). 
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